MUJI 0.5 mm Gel Ink Pen Set – Black (Pack of 6)

Product Information

Ozempic pens come in 3 sizes. Each pen holds 4 maintenance doses of either 0.5 mg, 1 mg, or 2 mg of medicine given once weekly and will last for one month. Key Points

One mL of solution contains 2.27 mg of semaglutide. One pre-filled pen contains 6.8 mg semaglutide in 3 mL solution The mean volume of distribution of semaglutide following subcutaneous administration in patients with type 2 diabetes was approximately 12.5 L. Semaglutide was extensively bound to plasma albumin (>99%). Do not share your Ozempic ® pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. What is the most important information I should know about Ozempic ®? The efficacy of semaglutide was not impacted by age, gender, race, ethnicity, BMI at baseline, body weight (kg) at baseline, diabetes duration and level of renal function impairment.Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. You can use the Ozempic dose counter on your pen to see how much medicine is left in the pen. If you cannot dial your dose, there is not enough medicine in the pen for your dose. The dose counter is found on the front of your pen between the Ozempic label and the dose pointer.

Treatment with semaglutide demonstrated sustained, statistically superior and clinically meaningful reductions in HbA 1c and body weight for up to 2 years compared to placebo and active control treatment (sitagliptin, insulin glargine, exenatide ER and dulaglutide). Semaglutide reduces body weight and body fat mass through lowered energy intake, involving an overall reduced appetite. In addition, semaglutide reduces the preference for high fat foods.The needle is covered by two caps. You must remove both caps. If you forget to remove both caps you will not inject any wegovy. are pregnant or breastfeeding or plan to become pregnant or breastfeed. It is not known if Ozempic ® will harm your unborn baby or passes into your breast milk. You should stop using Ozempic ® 2 months before you plan to become pregnant. American Diabetes Association (ADA) classified hypoglycaemia occurred in 11.3% (0.3 events/patient year) of patients when semaglutide 1 mg was added to SGLT2 inhibitor in SUSTAIN 9 compared to 2.0% (0.04 events/patient year) of placebo-treated patients. Severe hypoglycaemia was reported in 0.7% (0.01 events/patient year) and 0% of patients, respectively. Before using Ozempic ®, tell your health care provider if you have any other medical conditions, including if you: After one year of treatment, a weight loss of ≥5% and ≥10% was achieved for more subjects with semaglutide 0.5 mg (46% and 13%) and 1 mg (52 – 62% and 21 – 24%) compared with the active comparators sitagliptin (18% and 3%) and exenatide ER (17% and 4%).

The effect of semaglutide on cardiac repolarization was tested in a thorough QTc trial. Semaglutide did not prolong QTc intervals at dose levels up to 1.5 mg at steady state.

This is not all the information you need to know about Ozempic for safe and effective use. Review the full Ozempic information here, and discuss this information with your doctor or other health care provider. References changes in vision. Tell your health care provider if you have changes in vision during treatment with Ozempic ®. In developmental toxicity studies in rabbits and cynomolgus monkeys, increased pregnancy loss and slightly increased incidence of foetal abnormalities were observed at clinically relevant exposures. The findings coincided with marked maternal body weight loss of up to 16%. Whether these effects are related to the decreased maternal food consumption as a direct GLP-1 effect is unknown.

At week 40, the increase in pulse rate for semaglutide (0.5 mg and 1 mg) and dulaglutide (0.75 mg and 1.5 mg) was 2.4, 4.0, and 1.6, 2.1, beats/min, respectively.Results target the on-treatment period in all randomised subjects (analyses based on mixed models for repeated measurements or multiple imputation). Semaglutide did not change the overall exposure or C max of metformin following dosing of 500 mg twice daily over 3.5 days. If it stops at 0.5, this means at least 0.5 mg is left in your pen. If the dose counter stops before 0.5 mg, there is not enough medicine for a full 0.5 mg dose Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. At Week 5, your doctor will increase the dose to 0.5 mg once a week. If, after at least 4 weeks on the 0.5 mg dose, you need further blood sugar control, your doctor may increase your dose to 1 mg once a week. There is a separate pen for this dose and you will need a new prescription.